18.25
-3.95%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Apollomics
Its shares trade under the ticker APLM. It has been listed since 26 November 2021. In the fiscal year to 31 December 2025, it reported revenue of $8.5m and a net loss of $10.9m. At that date it held total assets of $6.7m and shareholders' equity of −$3.2m.
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California. The company went IPO on 2021-11-26. The firm is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics has a pipeline of approximately nine drug candidates across multiple programs, six of which are in the clinical-stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is in a Phase II multicohort clinical trial in the United States. The firm is also developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Nov 2021
- Website
- apollomicsinc.com ↗
- Head office
- 668 ARROW GRAND CIR, COVINA, CA, 91772
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Hong - Jung ChenChairman of the Board, Chief Executive Officer
- Mr. Wey - Chuan GauChief Financial Officer, Director
- Mr. Yung-Fong SongChief Strategy Officer
- Mr. Yi - Kuei ChenIndependent Director
- Ms. Noha GeorgesIndependent Director
- Mr. Sou-Shan WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is a clinical-stage biotechnology firm focused on oncology therapies.
- Headquartered in Foster City, California, with an IPO in 2021.
- Pipeline includes nine drug candidates, six in clinical development.
Weaknesses
- No specific financial data provided for the company.
- No details on current revenue or profitability metrics.
- No information on market share or competitive positioning.
Opportunities
- Potential for vebreltinib (APL-101) to address unmet medical needs in non-small cell lung cancer.
- Upgrades to uproleselan (APL-106) could expand its use in hematologic cancers.
- Combination therapies with other treatment options may enhance market potential.
Threats
- Clinical trials for drug candidates may face delays or failures.
- Competition in oncology therapies could impact market entry.
- Regulatory approvals for new therapies may be challenging.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.